Febuxostat is useful for cancer-associated hyperuricemia in patients with hematologic malignancies

Tumor lysis syndrome (TLS) causes hyperuricemia in patients with malignancies under chemotherapeutic treatment. Lowering serum uric acid (S -UA) levels is the most important. Febuxostat has been officially used for chemotherapy -associated hyperuricemia since May 2016 in Japan. Rasburicase and febuxostat reduce S -UA. Rasburicase is effective for high -risk TLS, and febuxostat for low -intermediate risk. Here, febuxostat was evaluated as a treatment for cancer -related hyperuricemia after becoming officially employed for TLS (June 2016 -November 2017) . Sixty milligram was taken by mouth. The first chemotherapeutic treatment was started within a day after the first 60 mg dosing. The primary endpoint was S -UA normalization ( 7 mg / dL) on day 7 of chemotherapy.